Addex Therapeutics Ltd (ADXN)
NASDAQ: ADXN · Real-Time Price · USD
7.49
-0.31 (-3.97%)
Nov 28, 2025, 4:00 PM EST - Market closed
Addex Therapeutics Revenue
Addex Therapeutics had revenue of 36.38K CHF in the quarter ending June 30, 2025, a decrease of -68.45%. This brings the company's revenue in the last twelve months to 167.29K, down -79.93% year-over-year. In the year 2024, Addex Therapeutics had annual revenue of 410.04K, down -74.64%.
Revenue (ttm)
167.29K CHF
Revenue Growth
-79.93%
P/S Ratio
36.85
Revenue / Employee
83,643 CHF
Employees
2
Market Cap
7.75M USD
Revenue Chart
* This company reports financials in CHF.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 410.04K | -1.21M | -74.64% |
| Dec 31, 2023 | 1.62M | 172.23K | 11.92% |
| Dec 31, 2022 | 1.44M | -1.71M | -54.18% |
| Dec 31, 2021 | 3.15M | -725.84K | -18.71% |
| Dec 31, 2020 | 3.88M | 1.05M | 36.89% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
ADXN News
- 2 months ago - Addex Therapeutics Ltd (ADXN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - Addex Therapeutics Reports 2025 Half Year and Second Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Addex Therapeutics to Report 2025 Half-year and Second Quarter Financial Results on September 30, 2025 and Host Conference Call on October 1, 2025 - GlobeNewsWire
- 2 months ago - Addex Appoints Bank of New York Mellon as Depositary Bank - GlobeNewsWire
- 5 months ago - Stalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder Programs - GlobeNewsWire
- 5 months ago - Addex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric Disorders - GlobeNewsWire
- 5 months ago - Addex Shareholders Approve All Resolutions at Annual General Meeting - GlobeNewsWire
- 5 months ago - Addex Therapeutics Reports Q1 2025 Financial Results and Provides Corporate Update - GlobeNewsWire